Table 2.

Clinicopathologic features of patients treated with gemcitabine

Low dCKHigh dCKP
Age (y)70.3 ± 8.159.8 ± 7.4<0.0006
Gender (M/F)3/617/6<0.04
Race (white/black)8/120/3NS
Tumor differentiation*
    Well/moderate (n = 12)48NS
    Poor (n = 10)28
Positive margins*
    Yes (n = 3)12NS
    No (n = 18)414
Clinical stage
    I02NS
    II31
    III514
    IV16
CA19-9 decrease ≥ 25%
    Yes (n = 7)34NS
    No (n = 15)213
Overall survival (mo)14.6 ± 7.321.7 ± 13.8<0.009
Overall survival following gemcitabine initiation (mo)10.0 ± 5.312.0 ± 9.3<0.04
Gemcitabine single agent
    Yes (n = 11)38NS
    No (n = 21)615
  • * This information was only available for patients who underwent surgical resection.